Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
De Maio E, Pacilio C, Gravina A, Morabito A, Di Rella F, Labonia V, Landi G, Nuzzo F, Rossi E, Silvestro P, Botti G, Di Bonito M, Curcio MP, Formichelli F, La Vecchia F, Staiano M, Maurea N, D'Aiuto G, D'Aiuto M, Thomas R, Signoriello G, Perrone F, de Matteis A. De Maio E, et al. Among authors: thomas r. BMC Cancer. 2007 Mar 20;7:50. doi: 10.1186/1471-2407-7-50. BMC Cancer. 2007. PMID: 17374151 Free PMC article. Clinical Trial.
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G, Comella P, Thomas R, Di Bonito M, Lapenta L, Capasso I, Botti G, Vallone P, De Rosa V, D'Aiuto G, Comella G. Frasci G, et al. Among authors: thomas r. Cancer Chemother Pharmacol. 2004 Jan;53(1):25-32. doi: 10.1007/s00280-003-0669-x. Epub 2003 Sep 26. Cancer Chemother Pharmacol. 2004. PMID: 14513281 Clinical Trial.
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, Gori S, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, de Matteis A. Nuzzo F, et al. Among authors: thomas r. Crit Rev Oncol Hematol. 2008 May;66(2):171-80. doi: 10.1016/j.critrevonc.2007.10.006. Epub 2007 Dec 21. Crit Rev Oncol Hematol. 2008. PMID: 18160303 Clinical Trial.
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Nuzzo F, Morabito A, Gravina A, Di Rella F, Landi G, Pacilio C, Labonia V, Rossi E, De Maio E, Piccirillo MC, D'Aiuto G, Thomas R, Rinaldo M, Botti G, Di Bonito M, Di Maio M, Gallo C, Perrone F, de Matteis A. Nuzzo F, et al. Among authors: thomas r. BMC Cancer. 2011 Feb 16;11:75. doi: 10.1186/1471-2407-11-75. BMC Cancer. 2011. PMID: 21324184 Free PMC article. Clinical Trial.
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G; Southern Italy Cooperative Oncology Group (SICOG). Frasci G, et al. Among authors: thomas r. Br J Cancer. 2006 Oct 23;95(8):1005-12. doi: 10.1038/sj.bjc.6603395. Br J Cancer. 2006. PMID: 17047649 Free PMC article. Clinical Trial.
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Frasci G, Comella P, D'Aiuto G, Thomas R, Capasso I, Elmo M, Botti G, Cortino GR, Lapenta L, De Rosa V, Vallone P, Petrillo A, Comella G. Frasci G, et al. Among authors: thomas r. Ann Oncol. 2000 Mar;11(3):367-71. doi: 10.1023/a:1008346708604. Ann Oncol. 2000. PMID: 10811508 Free article. Clinical Trial.
Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Di Bonito M, Rivellini F, Carteni G, De Lucia L, Maiorino L, D'Aniello R, Frezza P, Lapenta L, Comella G. Frasci G, et al. Among authors: thomas r. Breast Cancer Res Treat. 2000 Jul;62(2):87-97. doi: 10.1023/a:1006429205363. Breast Cancer Res Treat. 2000. PMID: 11016746 Clinical Trial.
8,426 results